NCT03621839 New CSF Biomarkers for Alzheimer's Disease
| NCT ID | NCT03621839 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Central Hospital, Nancy, France |
| Condition | Alzheimer Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 50,000 participants |
| Start Date | 2013-07-12 |
| Primary Completion | 2050-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 50,000 participants in total. It began in 2013-07-12 with a primary completion date of 2050-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Today, the Alzheimer's disease (AD) diagnosis is founded not only on clinical criteria but also on complementary examinations to confirm a physiopathological process of AD. In complex cases, lumbar punction could be necessary in order to measure Aβ peptides and Total and phosphorylated Tau but new biomarkers could be useful. The main objective of this project is to conserve these cerebrospinal fluids, collected in usual practice in order to validate new biomarkers for diagnosis, prognosis or therapeutic following of Alzheimer's disease and other dementia.
Eligibility Criteria
Inclusion Criteria: * Lumbar punction collected in usual practice in the context of dementia diagnosis Exclusion Criteria: * Absence of consent
Frequently Asked Questions
Who can join the NCT03621839 clinical trial?
This trial is open to participants of all sexes, studying Alzheimer Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03621839 currently recruiting?
Yes, NCT03621839 is actively recruiting participants. Visit ClinicalTrials.gov or contact Central Hospital, Nancy, France to inquire about joining.
Where is the NCT03621839 trial being conducted?
This trial is being conducted at Nancy, France.
Who is sponsoring the NCT03621839 clinical trial?
NCT03621839 is sponsored by Central Hospital, Nancy, France. The trial plans to enroll 50,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.